Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi’s Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
Where Today's News Shapes Tomorrow
